• Sofdra (sofpironium) topical gel, 12.45% is only approved in the USA and not marketed elsewhere
• Ecclock gel 5% is a different concentration and formulation than Sofdra, and was tested in different clinical studies
• Neither Ecclock nor any other 5% concentration of sofpironium bromide gel are approved for sale in the USA

Botanix Pharmaceuticals Ltd (ASX: BOT) is responding to the reported announcement by President Trump on Telegram of a proposed executive order in relation to 'Prescription Drug and Pharmaceutical Prices'. Botanix is aware that the proposed executive order is focused on reducing costs of pharmaceuticals by instituting a 'most favored nation's policy' whereby the US will pay the same price as the nation that pays the lowest price for a drug, anywhere in the world. Botanix has stated that its lead product, Sofdra (sofpironium) topical gel, 12.45%, is only approved in the USA and is not marketed in any other jurisdiction worldwide by Botanix or any other party. Additionally, Ecclock gel 5%, which contains sofpironium bromide, is a different concentration and formulation than Sofdra, and was tested in different clinical studies and populations. Neither Ecclock nor any other 5% concentration of sofpironium bromide gel are approved for sale in the USA, and Sofdra is also not approved for sale in Japan. Based on this information, Botanix does not consider that it is likely to be subject to price reductions based on sales of Sofdra outside the USA, as there are none.